- EQS-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
- EQS-News: Lucinda Crabtree to Join MorphoSys as Chief Financial Officer
- EQS-News: Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023
- EQS-News: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs
- EQS-Adhoc: Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters
- EQS-News: MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024
- EQS-News: MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
- EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
More ▼
Key statistics
On Thursday, MorphoSys AG (MOR:BRN) closed at 12.22, 1.53% above its 52-week low of 12.04, set on Dec 21, 2022.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.22 |
---|---|
High | 12.22 |
Low | 12.22 |
Bid | 12.32 |
Offer | 12.35 |
Previous close | 12.22 |
Average volume | -- |
---|---|
Shares outstanding | 34.23m |
Free float | 33.66m |
P/E (TTM) | -- |
Market cap | 487.81m EUR |
EPS (TTM) | -4.43 EUR |
Data delayed at least 15 minutes, as of Dec 22 2022.
More ▼